Recent Advances in the Treatment of Hematologic Malignancies

Recent Advances in the Treatment of Hematologic Malignancies is organized by Med-IQ and will be held from Oct 11, 2018 - Oct 10, 2019.

Target Audience:
This activity is intended for community oncologists and community hematologic oncologists.

Accreditation/Designation Statements:
Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Conference Description:
In this 30-minute webcast, expert faculty explore recent advances in the treatment of hematologic malignancies. In particular, CAR T-cell therapy for relapsed and refractory diffuse large B-cell lymphoma and FLT3-targeted treatment in AML are discussed.

Statement of Need:
The annual American Society of Clinical Oncology (ASCO) meeting showcases cutting-edge research on treatment modalities and new therapies in the field of oncology. It is important for oncologists who manage patients with hematologic malignancies to be aware of data presented at ASCO 2018 on the effectiveness of novel treatment strategies, including CAR T-cell therapy and other novel targeted agents.

Learning Objectives:
Upon completion, participants should be able to:
• Describe recent clinical data supporting the use of novel agents that target FLT3 for the treatment of AML
• Identify aspects of current and emerging CAR T-cell therapies, including targets, activity, and toxicity.